N-ALKANOYL-N-(1-(HETEROCYCLIC AMINO)ISOPROPYL)-2-AMINOPYRIDINES

1,178,229. N - (Alkyleneiminoalkyl)- aminopyridine derivatives. FARBENFABRIKEN BAYER A.G. 25 Sept., 1968 [25 Sept., 1967; 31 Aug., 1968], No. 45513/68. Heading C2C. The invention comprises novel N-(alkyleneiminoalkyl)-aminopyridines of the Formula I wherein X is a bivalent alkylene radical having from 5 to 9 carbon atoms, which may be branched at least once, may be saturated or unsaturated, and which forms a saturated or unsaturated 5- to 8-membered heterocylic ring with the N atom, and Y is H or COR111, wherein R111 is H, an alkyl or alkenyl group having up to 4 C atoms and the acid addition salts thereof. Compounds of the above general Formula I in which Y is COR111 are prepared by acylating the corresponding compound of Formula I in which Y is H, the latter compounds being obtained by alkylating the corresponding aminopyridines with the appropriate 1-alkyleneimino-isopropyl halide in the presence of sodium amide and separating the desired compound from the molar of N - pyridyl - 1 - alkyleneimino - 2 - aminopropanes and N-pyridyl-2-alkyleneimino- 1-aminopropanes obtained, or by heating in the presence of copper bronze and K 2 CO 3 the corresponding halopyridines with the appropriate 1- alkyleneimino - 2 - aminopropanes, resulting from the reductive amination of the alkyleneimino-acetone obtained by reacting chloroacetone with the appropriate alkyleneimine. N - [1 - cis - (2,6 - Dimethylpiperidino) - isopropyl]-2-aminopyridine is prepared by reducing with LiAlH 4 N-[a-(2-pyridylamino)-propionyl]-cis-2,6-dimethylpendine resulting from the reaction of 2-aminopyridine with N-α- chloropropionyl - cis - 2,6 - dimethylpiperidine obtained by acylating cis-2,6-dimethylpiperidine with α-chloro-propionyl chloride. Cis- and trans-2,4-Dimethyl-, 2,3-dimethyl- and 3,4-dimethyl-piperidine are obtained by the hydrogenation using a Ru/Al 2 O 3 catalyst of 2,4-, 2,3- and 3,4-lutidines respectively. Pharmaceutical compositions, having analgesic activity and suitable for oral, rectal or parenteral administration, contain compounds of the general Formula I in which Y represents COR111 or acid addition salts thereof as the active ingredients in admixture with solid or liquid diluents or carriers.